

Figure S1: No genomic DNA contamination and amplification products of the expected size were found. Agarose gel of amplification products obtained using mouse *Ffar2* primers for BaF cells, expected product size of 80pb, and human *Ffar2* primers for HL-60 cells, expected product size of 177 pb.



Figure S2: CMTB regulates *Ffar2* expression at the transcriptional level independently of an induction of STAT3. *Ffar2* expression after 8 h of incubation with CMTB with a 1 h pre-treatment with 2 µg/ml actinomycin D (A). Ratio phospho-Y705-STAT3/STAT3 in BaF cells incubated for 24h with CMTB 10µM (B), trichostatin A 50 nM (C), imatinib mesylate 0,5µM (D) and propionate 2 mM (E). Control (CT) cells were treated with the respective vehicle. *** *P* <0.001 *vs* vehicle (Veh). Results of 3 independent experiments are shown.



Figure S3. Reduced cell proliferation is associated with increased *Ffar2* expression *in vitro* in two human leukemic cell lines. Cell proliferation and *Ffar2* expression in HL-60 cells after 24 h incubation in presence of trichostatin A (A, B) and doxorubicin (IC, D). Cell proliferation and *Ffar2* expression in U937 cells after 24 h incubation in presence of trichostatin A (E, F) and doxorubicin (G, H). Results of 3 independent experiments performed at least in triplicate are shown. ** *P* <0.01, *** *P* <0.001 *vs* vehicle (Veh).